(19)
(11) EP 3 638 696 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.06.2024 Bulletin 2024/26

(45) Mention of the grant of the patent:
06.03.2024 Bulletin 2024/10

(21) Application number: 18732064.3

(22) Date of filing: 18.06.2018
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
 A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/505; C07K 2317/22; C07K 2317/24; C07K 2317/41; C07K 2317/732; C07K 2317/734; C07K 2317/76; C07K 2317/94; A61K 45/06; C07K 16/2875; A61P 35/02; A61K 31/706; A61K 39/39558
 
C-Sets:
  1. A61K 39/39558, A61K 2300/00;
  2. A61K 31/706, A61K 2300/00;
(86) International application number:
PCT/EP2018/066144
(87) International publication number:
WO 2018/229303 (20.12.2018 Gazette 2018/51)

(54)

USE OF ANTI CD70 ANTIBODY ARGX-110 TO TREAT ACUTE MYELOID LEUKAEMIA

ANWENDUNG VON ANTI CD70 ANTIKÖRPER ARGX-110, UM AKUTE MYELOID LEUKEMIE ZU BEHANDELN

UTILISATION DE L'ANTICORPS ANTI-CD70 ARGX-110 POUR TRAITER LA LEUCÉMIE MYÉLOÏDE AIGUË

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 16.06.2017 GB 201709677

(43) Date of publication of application:
22.04.2020 Bulletin 2020/17

(60) Divisional application:
24160069.1 / 4389142

(73) Proprietors:
  • argenx BV
    9052 Zwijnaarde (Ghent) (BE)
  • University of Bern
    3012 Bern (CH)

(72) Inventors:
  • LEUPIN, Nicolas
    B-9052 Gent (BE)
  • VAN ROMPAEY, Luc
    B-9052 Gent (BE)
  • DE HAARD, Hans
    B-9052 Gent (BE)
  • OCHSENBEIN, Adrian
    3032 Hinterkappelen (CH)
  • RIETHER, Carsten
    3012 Bern (CH)

(74) Representative: Boult Wade Tennant LLP 
Salisbury Square House 8 Salisbury Square
London EC4Y 8AP
London EC4Y 8AP (GB)


(56) References cited: : 
WO-A1-2012/123586
   
  • DEMPKE WOLFRAM C M ET AL: "Second- and third-generation drugs for immuno-oncology treatment-The more the better?", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 74, 10 February 2017 (2017-02-10), pages 55-72, XP029933747, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2017.01.001
  • J. JACOBS ET AL: "CD70: An emerging target in cancer immunotherapy", PHARMACOLOGY AND THERAPEUTICS., vol. 155, November 2015 (2015-11), pages 1-10, XP055289894, GB ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2015.07.007
  • CARSTEN RIETHER ET AL: "CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 214, no. 2, 28 December 2016 (2016-12-28), pages 359-380, XP055735891, US ISSN: 0022-1007, DOI: 10.1084/jem.20152008
  • MAY KUNG SUTHERLAND ET AL: "5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia", MABS LANDES BIOSCIENCE, vol. 24, 1 July 2010 (2010-07-01), pages 440-448, XP055096014, DOI: 10.4161/mabs.12203
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).